Adynovate Is An Extended Half-Life Recombinant Factor Viii (Rfviii) Treatment, Using Established Technology (Controlled Pegylation), For Hemophilia A Patients. This Option Offers Lower Weekly Infusion Rates Than Standard Fviii, Providing Excellent Prophylactic Coverage. Takeda Pharma Has Expanded Its Innovative Rare Diseases Portfolio In India With The Launch Of Adynovate, An Innovative Extended Half-Life Recombinant Factor Viii (Rfviii) Treatment, Using Established Technology (Controlled Pegylation), For Haemophilia A Patients, A Company Statement Said. It Also Said That Adynovate, In Combination With Mypkfit, The First And Only Fdaapproved Application, Offers Personalised And Interactive Prophylaxis Treatment Option That Enables Both Healthcare Professionals And Patients In Real-Time Monitoring Of Factor Viii Levels From The Comfort Of Their Homes On Phone Thereby Adapting Their Activity Decisions Accordingly And Help Improve Their Quality Of Life. Alerts Are Sent To Patients On Prophylaxis When Their Estimated Factor Viii Levels Are Low, And Reminds Them When Their Infusions Are Due, Thereby Providing Excellent Prophylactic Coverage. Administered In Three Steps With The Baxject Iii System, Adynovate Eliminates The Need To Disinfect The Vial, As Vials Are Already Assembled In The System Housing. It Can Be Stored At Room Temperature Not To Exceed 30
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!